18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study

18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study

Abstract Purpose This study evaluated the ability of 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorothymidine (FLT) imaging with positron emission tomography (PET) to measure early response to endocrine therapy from baseline to just prior to surgical resection in estrogen receptor positive (ER+) breast...

Full description

Bibliographic Details
Main Authors: Perrin E. Romine, Lanell M. Peterson, Brenda F. Kurland, Darrin W. Byrd, Alena Novakova-Jiresova, Mark Muzi, Jennifer M. Specht, Robert K. Doot, Jeanne M. Link, Kenneth A. Krohn, Paul E. Kinahan, David A. Mankoff, Hannah M. Linden
Format: Article
Language:English
Published: BMC 2021-08-01
Series:Breast Cancer Research
Subjects:
FDG-PET
FLT-PET
Ki-67
ER+ breast cancer
Aromatase inhibitors
Online Access:https://doi.org/10.1186/s13058-021-01464-1

Internet

https://doi.org/10.1186/s13058-021-01464-1

Similar Items